RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Standard BioTools Stock

Standard BioTools Revenue 2024

Standard BioTools Revenue

203.19 M USD

Ticker

LAB

ISIN

US34385P1084

WKN

A0RADJ

In 2024, Standard BioTools's sales reached 203.19 M USD, a 91.08% difference from the 106.34 M USD sales recorded in the previous year.

The Standard BioTools Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2027e314.4116,05
2026e280.4917,99
2025e234.7321,49
2024e203.1924,83
2023106.3447,44
202297.937,90
2021130.653,14
2020138.160,32
2019117.254,86
201811354,51
2017101.951,03
2016104.455,94
2015114.759,37
2014116.563,18
201371.271,63
201252.370,75
201142.969,23
201033.665,48
200925.454,72
200815.345,75
20077.352,05
20066.456,25
20057.737,66

Standard BioTools Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Standard BioTools, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Standard BioTools from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Standard BioTools’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Standard BioTools. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Standard BioTools’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Standard BioTools’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Standard BioTools’s growth potential.

Standard BioTools Revenue, EBIT and net profit per share

DateStandard BioTools RevenueStandard BioTools EBITStandard BioTools Net Income
2027e314.41 M undefined-6.67 M undefined-7.47 M undefined
2026e280.49 M undefined-25.81 M undefined-18.68 M undefined
2025e234.73 M undefined-85.65 M undefined-76.59 M undefined
2024e203.19 M undefined-139.53 M undefined20.55 M undefined
2023106.34 M undefined-63.04 M undefined-74.66 M undefined
202297.9 M undefined-116.2 M undefined-190.1 M undefined
2021130.6 M undefined-67.5 M undefined-59.2 M undefined
2020138.1 M undefined-51 M undefined-53 M undefined
2019117.2 M undefined-51.9 M undefined-64.8 M undefined
2018113 M undefined-48.2 M undefined-59 M undefined
2017101.9 M undefined-58.4 M undefined-60.5 M undefined
2016104.4 M undefined-73.2 M undefined-76 M undefined
2015114.7 M undefined-54.2 M undefined-53.3 M undefined
2014116.5 M undefined-41.1 M undefined-52.8 M undefined
201371.2 M undefined-17.4 M undefined-16.5 M undefined
201252.3 M undefined-18.1 M undefined-19 M undefined
201142.9 M undefined-15.6 M undefined-32.4 M undefined
201033.6 M undefined-14.6 M undefined-16.9 M undefined
200925.4 M undefined-18 M undefined-19.1 M undefined
200815.3 M undefined-29.5 M undefined-29.5 M undefined
20077.3 M undefined-23.5 M undefined-25.5 M undefined
20066.4 M undefined-21.7 M undefined-23.6 M undefined
20057.7 M undefined-16.5 M undefined-16.4 M undefined

Standard BioTools stock margins

The Standard BioTools margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Standard BioTools. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Standard BioTools.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Standard BioTools's sales revenue. A higher gross margin percentage indicates that the Standard BioTools retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Standard BioTools's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Standard BioTools's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Standard BioTools's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Standard BioTools. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Standard BioTools's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Standard BioTools Margin History

Standard BioTools Gross marginStandard BioTools Profit marginStandard BioTools EBIT marginStandard BioTools Profit margin
2027e47.44 %-2.12 %-2.38 %
2026e47.44 %-9.2 %-6.66 %
2025e47.44 %-36.49 %-32.63 %
2024e47.44 %-68.67 %10.11 %
202347.44 %-59.28 %-70.21 %
202237.9 %-118.69 %-194.18 %
202153.14 %-51.68 %-45.33 %
202060.32 %-36.93 %-38.38 %
201954.86 %-44.28 %-55.29 %
201854.51 %-42.65 %-52.21 %
201751.03 %-57.31 %-59.37 %
201655.94 %-70.11 %-72.8 %
201559.37 %-47.25 %-46.47 %
201463.18 %-35.28 %-45.32 %
201371.63 %-24.44 %-23.17 %
201270.75 %-34.61 %-36.33 %
201169.23 %-36.36 %-75.52 %
201065.48 %-43.45 %-50.3 %
200954.72 %-70.87 %-75.2 %
200845.75 %-192.81 %-192.81 %
200752.05 %-321.92 %-349.32 %
200656.25 %-339.06 %-368.75 %
200537.66 %-214.29 %-212.99 %

Standard BioTools Aktienanalyse

What does Standard BioTools do?

Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Standard BioTools's Sales Figures

The sales figures of Standard BioTools originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Standard BioTools’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Standard BioTools's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Standard BioTools’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Standard BioTools stock

How much revenue did Standard BioTools generate this year?

Standard BioTools has achieved a revenue of 203.19 M USD this year.

How much was the turnover of the company Standard BioTools compared to the previous year?

The revenue of Standard BioTools has increased by 91.08% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Standard BioTools?

The revenue of Standard BioTools is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Standard BioTools measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Standard BioTools so important for investors?

The revenue of Standard BioTools is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Standard BioTools pay?

Over the past 12 months, Standard BioTools paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Standard BioTools is expected to pay a dividend of 0 USD.

What is the dividend yield of Standard BioTools?

The current dividend yield of Standard BioTools is .

When does Standard BioTools pay dividends?

Standard BioTools pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Standard BioTools?

Standard BioTools paid dividends every year for the past 0 years.

What is the dividend of Standard BioTools?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Standard BioTools located?

Standard BioTools is assigned to the 'Health' sector.

Wann musste ich die Aktien von Standard BioTools kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Standard BioTools from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.

When did Standard BioTools pay the last dividend?

The last dividend was paid out on 8/10/2024.

What was the dividend of Standard BioTools in the year 2023?

In the year 2023, Standard BioTools distributed 0 USD as dividends.

In which currency does Standard BioTools pay out the dividend?

The dividends of Standard BioTools are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Standard BioTools stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Standard BioTools

Our stock analysis for Standard BioTools Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Standard BioTools Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.